Prevalence and predictive value of intermittent viremia with combination hiv therapy
Summary
This summary is machine-generated.Intermittent viremia, or brief detectable HIV RNA levels, is common in patients on antiretroviral therapy. This study found it does not increase the risk of virologic failure, suggesting treatment changes may not be needed.
Area Of Science
- Virology
- Immunology
- Infectious Diseases
Background
- Antiretroviral therapy (ART) aims for virologic suppression in HIV patients.
- Intermittent low-level viremia (HIV RNA >50 copies/mL) is observed, but its clinical impact is unclear.
Purpose Of The Study
- To investigate if intermittent viremia predicts virologic failure (HIV RNA >200 copies/mL).
Main Methods
- Retrospective analysis of two cohorts: ACTG 343 (n=241) and Merck 035 (n=13).
- Assessed association between intermittent viremia and virologic failure.
- Analyzed drug resistance and viral replication levels.
Main Results
- Intermittent viremia occurred in 40% of ACTG 343 patients; it did not predict virologic failure (RR 0.76, CI 0.29-1.72).
- In Merck 035, intermittent viremia correlated with higher viral replication (P=.03) but not virologic failure.
- No evidence of drug resistance evolution was found.
Conclusions
- Intermittent viremia is frequent but not associated with virologic failure in patients on initial combination ART.
- Treatment adjustments may not be necessary for managing intermittent viremia to maintain long-term suppression.
View abstract on PubMed